I want to learn estrogen PHARMACOLOGY give me mcqs assertion reason type and fill inthe blank questions and detailed explanations so that ican learn use kd tripati, katzung , good man and gillman as reference

Reading File

Finding Sources

Reading File

I now have comprehensive, authoritative content. Let me compile the full question set with detailed explanations.

Estrogen Pharmacology - Complete Question Bank

References: Goodman & Gilman's Pharmacological Basis of Therapeutics (G&G), Katzung's Basic & Clinical Pharmacology 16e (K), KD Tripathi's Essentials of Medical Pharmacology (KDT)

SECTION 1: MULTIPLE CHOICE QUESTIONS (MCQs)

Q1. The most potent naturally occurring estrogen in humans is:

A. Estrone (E1) B. Estriol (E3) C. 17β-Estradiol (E2) D. Equilin

Answer: C - 17β-Estradiol

Explanation: 17β-Estradiol (E2) is the most potent naturally occurring estrogen for both ERα- and ERβ-mediated actions. The order of potency is: Estradiol (E2) > Estrone (E1) > Estriol (E3). All three contain a phenolic A ring with a hydroxyl group at carbon 3 and a β-OH or ketone at position 17 of ring D. The phenolic A ring is the principal structural feature responsible for selective high-affinity binding to both receptors. In premenopausal women, estradiol is the main secretory product of the ovaries. (G&G, Ch. 48; KDT Ch. 22)

Q2. The enzyme responsible for converting androgens to estrogens (aromatization) is:

A. 17β-HSD B. 3β-HSD C. Aromatase (CYP19) D. 5α-reductase

Answer: C - Aromatase (CYP19)

Explanation: Aromatase (CYP19) catalyzes aromatization of the A ring of androstenedione or testosterone to yield estrogens. It uses NADPH and molecular oxygen as cosubstrates. A flavoprotein NADPH-cytochrome P450 reductase is also essential. Aromatase is expressed in ovarian granulosa cells, testicular Sertoli and Leydig cells, adipose stroma, placental syncytiotrophoblasts, bone, and brain. This is why adipose tissue is an important extra-gonadal source of estrogen (especially after menopause). 5α-reductase converts testosterone to the more potent DHT. (G&G, Ch. 48)

Q3. Ethinyl substitution at C17 position of estradiol is done to:

A. Increase affinity for ERβ selectively B. Increase oral potency by inhibiting first-pass hepatic metabolism C. Reduce the risk of thromboembolic events D. Enhance binding to progesterone receptor

Answer: B

Explanation: Ethinyl substitution at the C17 position greatly increases oral potency by inhibiting first-pass hepatic metabolism. This is why ethinyl estradiol is a highly effective oral estrogen used in combined oral contraceptive pills (OCPs), whereas natural estradiol has poor oral bioavailability due to extensive hepatic first-pass effect. Parenteral routes (transdermal, vaginal) can deliver natural estradiol without this problem. (G&G, Ch. 48; K, Ch. 40)

Q4. Estrogen receptors belong to which superfamily?

A. Receptor tyrosine kinases B. G protein-coupled receptors C. Nuclear receptor superfamily (ligand-activated transcription factors) D. Ligand-gated ion channels

Answer: C

Explanation: Both ERα and ERβ are members of the nuclear receptor superfamily and function as ligand-activated transcription factors. After entering the cell by passive diffusion, estrogen binds to ER in the nucleus. The hormone-ER complex then dissociates from heat shock protein 90 (HSP90), dimerizes, binds to estrogen response elements (EREs) in the promoter regions of target genes, recruits coactivators, and initiates transcription. A separate GPCR - GPER (GPR30) - also mediates some rapid non-genomic effects of estrogen. (G&G, Ch. 48)

Q5. Which statement about ERα vs ERβ is CORRECT?

A. ERβ is predominantly responsible for breast cancer cell growth regulation B. ERα homodimers and ERα/ERβ heterodimers are the only combinations possible C. When coexpressed with ERα, ERβ can inhibit ERα-mediated transcriptional activation D. ERα is predominantly expressed in bone but not in the uterus

Answer: C

Explanation: When ERβ is coexpressed with ERα, ERβ can inhibit ERα-mediated transcriptional activation in many cases. ERα is believed to be the predominant form responsible for growth regulation in breast cancers. Homodimers of ERα, homodimers of ERβ, and ERα/ERβ heterodimers can all be produced depending on receptor complement in a given cell. Both receptors are expressed broadly - uterus, breast, bone, brain, cardiovascular system. (G&G, Ch. 48)

Q6. The mechanism of the LH surge at mid-cycle involves:

A. Progesterone exerting negative feedback on the hypothalamus B. A brief stimulatory effect of high estrogen levels on the pituitary C. Kisspeptin inhibiting GnRH release in the arcuate nucleus D. FSH directly triggering LH release from the pituitary

Answer: B

Explanation: At low levels, estrogen exerts NEGATIVE feedback on the pituitary (follicular phase suppression). However, at higher sustained levels (as the dominant follicle grows), estrogen switches to a POSITIVE feedback effect - it briefly stimulates the pituitary gonadotropes to release a massive surge of LH (and to a lesser extent FSH). This LH surge triggers ovulation. Kisspeptin normally stimulates GnRH - estrogen reduces kisspeptin in the arcuate nucleus (negative feedback), but kisspeptin neurons in the anteroventral periventricular nucleus (AVPV) are stimulated by estrogen to drive the LH surge. (G&G, Ch. 48; KDT Ch. 22)

Q7. Which of the following is NOT an effect of estrogen?

A. Proliferation of uterine endometrium B. Induction of progesterone receptors in the endometrium C. Increased bone resorption (net osteoporosis) D. Increased LDL clearance and decreased LDL levels

Answer: C

Explanation: Estrogen PROTECTS against osteoporosis - it inhibits osteoclast activity and reduces bone resorption. Estrogen deficiency (e.g., after menopause) leads to increased bone resorption and osteoporosis. Estrogen's beneficial lipid effects include decreasing LDL and increasing HDL. It stimulates endometrial proliferation and induces PR expression (enabling progesterone to exert its effects in the secretory phase). The protective effect on bone is the basis for using HRT in postmenopausal women. (G&G, Ch. 48; K, Ch. 40)

Q8. Which route of estrogen administration AVOIDS first-pass hepatic metabolism and therefore causes fewer changes in hepatic protein synthesis?

A. Oral conjugated equine estrogens B. Oral ethinyl estradiol C. Transdermal estradiol patch D. Oral micronized estradiol

Answer: C

Explanation: Transdermal estradiol (and vaginal preparations) bypass first-pass hepatic metabolism, delivering estradiol directly into the systemic circulation. Oral estrogens, including conjugated equine estrogens and ethinyl estradiol, pass through the portal circulation first, stimulating hepatic synthesis of binding globulins (SHBG, CBG, TBG), clotting factors, angiotensinogen, and other proteins. Transdermal estrogens have a lower risk of VTE and are preferred in women with risk factors for thrombosis. (G&G, Ch. 48; KDT Ch. 22)

Q9. Tamoxifen is metabolized by CYP2D6 to its most active metabolite:

A. N-desmethyltamoxifen B. 4-hydroxytamoxifen (endoxifen) C. Toremifene D. Fulvestrant

Answer: B

Explanation: Tamoxifen is extensively metabolized. CYP2D6 converts tamoxifen to 4-hydroxytamoxifen (endoxifen), which is a more potent SERM. This is clinically very important - strong CYP2D6 inhibitors (like fluoxetine, paroxetine) should be avoided in patients receiving tamoxifen for breast cancer because they reduce endoxifen levels and potentially decrease therapeutic efficacy. The initial plasma half-life of tamoxifen is 7-14 hours. N-desmethyltamoxifen is also a metabolite with ER affinity comparable to tamoxifen itself, but less potent than endoxifen. (G&G, Ch. 48; K, Ch. 40)

Q10. Raloxifene differs from tamoxifen in that raloxifene:

A. Has no effect on bone B. Acts as an estrogen agonist on uterine endometrium C. Does NOT increase risk of endometrial cancer D. Is used primarily for contraception

Answer: C

Explanation: This is a key distinguishing point. Tamoxifen acts as a partial estrogen AGONIST on the uterus, causing endometrial thickening and a ~2-fold increase in endometrial carcinoma risk. Raloxifene is INACTIVE on the uterus (neutral/slight antagonist), so it does NOT increase endometrial cancer risk. Both tamoxifen and raloxifene act as estrogen agonists on bone (anti-resorptive) and as antagonists on breast tissue. Both increase VTE risk. Raloxifene is approved for osteoporosis prevention/treatment and breast cancer risk reduction. A downside of raloxifene is worsening of vasomotor symptoms (hot flushes). (G&G, Ch. 48; K, Ch. 40)

SECTION 2: ASSERTION-REASON TYPE QUESTIONS

Format: A = Assertion, R = Reason

Options:

(A) Both A and R are true, and R is the correct explanation of A
(B) Both A and R are true, but R is NOT the correct explanation of A
(C) A is true but R is false
(D) A is false but R is true
(E) Both A and R are false

AR-1.

A: Ethinyl estradiol is more potent orally than natural 17β-estradiol.

R: The ethinyl group at C17 inhibits first-pass hepatic oxidative metabolism, thereby increasing oral bioavailability.

Answer: (A) - Both true, R correctly explains A

Explanation: Natural estradiol undergoes extensive first-pass metabolism in the liver and gut wall (mainly to estrone and estrone sulfate), resulting in very low oral bioavailability (~5%). The addition of the ethinyl group at the C17α position sterically hinders the 17-keto oxidation by hepatic enzymes, dramatically reducing first-pass metabolism and increasing oral potency by approximately 100-fold. This is why ethinyl estradiol, not estradiol, is used in oral contraceptives. (G&G, Ch. 48)

AR-2.

A: In menopause, FSH and LH levels are markedly elevated.

R: The loss of ovarian estrogen and inhibin removes negative feedback on the pituitary, causing unrestrained gonadotropin secretion.

Answer: (A) - Both true, R correctly explains A

Explanation: The ovaries produce estrogen and inhibin, both of which exert negative feedback on the pituitary. Estrogen primarily controls the amplitude of gonadotropin pulses; inhibin selectively suppresses FSH. When ovarian function declines at menopause, this negative feedback is lost, and FSH and LH levels rise markedly (FSH typically rises more than LH). FSH >40 IU/L confirms ovarian failure. G&G states: "When the ovaries are removed or cease to function, there is overproduction of FSH and LH, which are excreted in the urine." (G&G, Ch. 48)

AR-3.

A: Tamoxifen is used in breast cancer treatment but may cause endometrial cancer.

R: Tamoxifen is a pure estrogen antagonist at all tissues.

Answer: (C) - A is true but R is false

Explanation: This is a classic trap. Tamoxifen is NOT a pure antagonist - it is a SERM (Selective Estrogen Receptor Modulator) with mixed agonist/antagonist properties. It acts as an anti-estrogen (antagonist) on breast tissue, inhibiting breast cancer cell proliferation - this is the therapeutic basis. However, it acts as a partial AGONIST on uterine endometrium, causing endometrial thickening and a 2-fold increase in endometrial carcinoma risk. It is also agonistic on bone (protective) and on lipids (decreases LDL). The tissue-specific actions are explained by different ER conformations recruiting different coregulators in different cell types. (G&G, Ch. 48; K, Ch. 40)

AR-4.

A: Transdermal estradiol is preferred over oral estradiol in postmenopausal women with a history of deep vein thrombosis.

R: Oral estrogens increase hepatic synthesis of clotting factors and fibrinogen by first-pass portal delivery to the liver, while transdermal route bypasses this effect.

Answer: (A) - Both true, R correctly explains A

Explanation: Oral estrogens reaching the liver via the portal system stimulate hepatic synthesis of several proteins: clotting factors (particularly factors II, VII, IX, X), fibrinogen, angiotensinogen, SHBG, and CBG. This procoagulant state increases VTE risk. Transdermal estradiol avoids portal delivery to the liver and thus has a much lower effect on clotting factors - epidemiological data suggest it does not significantly increase VTE risk, making it the safer route in women with VTE history or risk factors. (G&G, Ch. 48; KDT Ch. 22)

AR-5.

A: Clomiphene (clomifene) induces ovulation in anovulatory women.

R: Clomiphene blocks estrogen receptors in the hypothalamus and pituitary, preventing negative feedback, thereby increasing GnRH, FSH, and LH secretion.

Answer: (A) - Both true, R correctly explains A

Explanation: Clomiphene is a SERM (triphenylethylene) that contains two isomers: zuclomiphene (cis - weak agonist) and enclomiphene (trans - potent antagonist). In anovulatory women, it acts as an estrogen antagonist in the hypothalamus and pituitary, blocking the negative feedback of endogenous estrogen. The hypothalamus and pituitary "perceive" an estrogen-deficient state and increase GnRH pulse frequency, leading to increased FSH and LH secretion. FSH drives follicular development, and the subsequent LH surge triggers ovulation. It is a first-line drug for ovulation induction in PCOS. (G&G, Ch. 48; K, Ch. 40; KDT Ch. 22)

AR-6.

A: Fulvestrant is called a "pure anti-estrogen" and does not increase endometrial cancer risk like tamoxifen.

R: Fulvestrant binds to ERα and ERβ, blocks dimerization, accelerates receptor degradation, and has NO agonist activity on any tissue.

Answer: (A) - Both true, R correctly explains A

Explanation: Fulvestrant (ICI 182,780) is a 7α-alkylamide derivative of estradiol that acts as a pure estrogen antagonist without any agonist activity. Unlike tamoxifen, it not only blocks the ER but also promotes receptor degradation (downregulation), and prevents receptor dimerization and nuclear translocation. Because it lacks agonist activity anywhere, it does not stimulate uterine endometrium and does not increase endometrial cancer risk. It is used as second-line hormonal therapy for metastatic breast cancer and ER+/HER2- advanced breast cancer (often combined with CDK4/6 inhibitors). (G&G, Ch. 48; K, Ch. 40)

AR-7.

A: In postmenopausal women, adipose tissue becomes an important source of circulating estrogen.

R: Adipose stromal cells express aromatase (CYP19), which converts adrenal androgens (primarily androstenedione) to estrone.

Answer: (A) - Both true, R correctly explains A

Explanation: After menopause, ovarian estradiol production essentially ceases. However, the adrenal cortex continues to produce androstenedione (and to a lesser extent testosterone). Adipose tissue stromal cells express aromatase, which converts androstenedione to estrone - the predominant estrogen in postmenopausal women. Obese postmenopausal women have higher circulating estrone levels due to increased aromatase activity in adipose tissue - this is why obesity increases the risk of estrogen-dependent cancers (endometrial, breast) in postmenopausal women. (G&G, Ch. 48)

AR-8.

A: Kisspeptin plays an important role in the onset of puberty.

R: Kisspeptin stimulates GnRH release via the GPR54 receptor; activating mutations of the kisspeptin gene can cause central precocious puberty.

Answer: (A) - Both true, R correctly explains A

Explanation: Kisspeptin neurons (located in the arcuate nucleus and anteroventral periventricular nucleus of the hypothalamus) signal through the GPR54 receptor on GnRH neurons to stimulate GnRH release. At puberty, the hypothalamic pulse generator is activated, partly through increases in leptin and IGF-1. Inactivating mutations in GPR54 or the kisspeptin gene cause hypogonadotropic hypogonadism (failure of puberty), while ACTIVATING mutations cause central precocious puberty. This establishes kisspeptin-GPR54 as the gate that opens puberty. Neurokinin B (via NK3R) also stimulates kisspeptin secretion. (G&G, Ch. 48)

SECTION 3: FILL IN THE BLANK QUESTIONS

FIB-1. The principal structural feature of estrogen responsible for selective high-affinity binding to both ERα and ERβ is the __________ ring.

Answer: Phenolic A ring

Explanation: The phenolic A ring (with a hydroxyl group at carbon 3) is the key structural determinant for ER binding. Most alkyl substitutions on the A ring impair binding. The phenolic A ring is what distinguishes estrogens from other steroids. Non-steroidal estrogens like diethylstilbestrol (DES) also mimic this phenolic hydroxyl arrangement, explaining their estrogenic activity. (G&G, Ch. 48)

FIB-2. In the ovary, the "two-cell theory" of estrogen biosynthesis states that __________ cells produce androgens under LH stimulation, which are then transferred to __________ cells where aromatase converts them to estradiol under FSH stimulation.

Answer: Theca cells ... Granulosa cells

Explanation: LH acts on theca cells via Gs-coupled receptors, activating adenylyl cyclase and increasing cAMP, which stimulates steroidogenesis (cholesterol → androstenedione → testosterone). These androgens diffuse to adjacent granulosa cells. FSH acts on granulosa cells to induce aromatase, which converts theca-derived androgens to estrogens (estradiol). This two-cell, two-gonadotropin model elegantly explains why both LH (for androgen substrate) and FSH (for aromatization) are needed for ovarian estrogen production. (G&G, Ch. 48; KDT Ch. 22)

FIB-3. Estrogen enters the cell by __________ and binds to ER in the nucleus, which is initially bound to __________ (a chaperone protein) in its inactive state.

Answer: Passive diffusion ... Heat Shock Protein 90 (HSP90)

Explanation: Being a lipophilic steroid hormone, estrogen crosses the plasma membrane by passive diffusion. In the nucleus, the unliganded ER exists as an inactive monomer associated with HSP90 (and other chaperones like p23, immunophilins). Estrogen binding causes a conformational change in the ER that dissociates HSP90, promotes receptor dimerization, and greatly increases affinity for DNA. The ER dimer then binds to EREs in target gene promoters and recruits coactivators to initiate transcription. (G&G, Ch. 48)

FIB-4. The ER complex, after binding DNA, increases transcription by binding to specific DNA sequences called __________ located in the promoter regions of target genes.

Answer: Estrogen Response Elements (EREs)

Explanation: EREs are palindromic DNA sequences (consensus: GGTCAnnnTGACC) located in the promoter regions of estrogen-responsive genes. The ER dimer binds EREs via its DNA-binding domain (DBD), which contains two zinc finger motifs. After ERE binding, the ER recruits coactivators (like SRC-1, p160 family) that bridge to the general transcription machinery via their HAT (histone acetyltransferase) activity, remodeling chromatin and initiating gene transcription. The nature of the gene activated depends on the tissue and the coactivators present. (G&G, Ch. 48)

FIB-5. Clomiphene citrate contains two isomers: __________ (cis) which is a weak estrogen agonist, and __________ (trans) which is a potent antagonist responsible for its ovulation-inducing effect.

Answer: Zuclomiphene ... Enclomiphene

Explanation: Clomiphene is a racemic mixture of zuclomiphene (cis isomer - weak agonist, longer half-life) and enclomiphene (trans isomer - potent antagonist, shorter half-life). The anti-estrogenic trans-isomer is the pharmacologically active component that blocks hypothalamic-pituitary ER, relieves negative feedback, and increases GnRH/FSH/LH. Enclomiphene alone is now being studied as a therapy for male hypogonadism (to increase endogenous testosterone without suppressing spermatogenesis - unlike exogenous testosterone). (G&G, Ch. 48)

FIB-6. Tamoxifen's most active metabolite is __________, generated by the enzyme __________. Therefore, co-administration with __________ inhibitors of this enzyme should be avoided.

Answer: 4-hydroxytamoxifen (endoxifen) ... CYP2D6 ... strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine)

Explanation: Tamoxifen → CYP2D6 → 4-hydroxytamoxifen (endoxifen), which has far greater anti-estrogenic potency than tamoxifen itself. Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) dramatically reduce endoxifen plasma levels, potentially compromising the anti-tumor effect of tamoxifen. This is a critical drug interaction in oncology. CYP2D6 poor metabolizers (genetic) also have lower endoxifen levels. CYP3A4 produces N-desmethyltamoxifen (less potent). (K, Ch. 40; G&G, Ch. 48)

FIB-7. Postmenopausal estrogen deficiency leads to increased bone resorption because estrogen normally __________ osteoclast activity. The net result is __________.

Answer: Inhibits (suppresses) ... Osteoporosis

Explanation: Estrogen promotes osteoblast survival and function while inhibiting osteoclast differentiation, activity, and lifespan. When estrogen is withdrawn (menopause), the restraint on osteoclasts is removed, causing a surge in bone resorption that outpaces bone formation. This leads to rapid loss of bone mineral density (BMD) - especially trabecular bone in the first 5-10 years post-menopause - and increased fracture risk (vertebral, hip). HRT or SERMs (raloxifene) can prevent this loss. Raloxifene is an estrogen agonist on bone, stabilizing BMD without stimulating the uterus. (G&G, Ch. 48, Ch. 65; K, Ch. 40)

FIB-8. The drug used for medical termination of pregnancy that acts as an antagonist at both progesterone and glucocorticoid receptors is __________.

Answer: Mifepristone (RU-486)

Explanation: Mifepristone is a 19-nor steroid that competitively antagonizes both progesterone receptors (causing decidual breakdown, cervical softening, and increased uterine sensitivity to prostaglandins) and glucocorticoid receptors. It also has a luteolytic effect and can serve as a postcoital contraceptive. For medical abortion (up to 9-10 weeks), mifepristone 200 mg is followed 24-48 hours later by misoprostol (a PGE1 analogue) to cause uterine contractions. The combination has ~97% efficacy. (K, Ch. 40)

FIB-9. Oral contraceptives primarily prevent pregnancy by __________. Additional mechanisms include thickening of cervical mucus and suppression of endometrial receptivity.

Answer: Suppressing ovulation (by inhibiting the midcycle LH surge via suppression of gonadotropin secretion)

Explanation: Combined OCPs contain an estrogen (usually ethinyl estradiol) plus a progestin. Together they suppress the hypothalamic-pituitary axis, preventing the midcycle LH surge and thereby preventing ovulation (the primary mechanism). Progestins additionally thicken cervical mucus (making it hostile to sperm), reduce fallopian tube motility, and cause endometrial atrophy (preventing implantation). This multi-level mechanism explains their >99% efficacy with perfect use. (K, Ch. 40; KDT Ch. 22)

FIB-10. Raloxifene, unlike tamoxifen, does not increase the risk of __________ cancer because it is __________ on the uterine endometrium (neither agonist nor antagonist).

Answer: Endometrial ... neutral/inactive (slight antagonist)

Explanation: Tamoxifen is a partial agonist on uterine endometrium, causing endometrial thickening and a ~2-fold increase in endometrial carcinoma risk (absolute risk ~0.6% over 5 years). Raloxifene lacks this agonist activity on the uterus because the ER-raloxifene complex adopts a conformation that fails to recruit the coactivators needed for endometrial stimulation. Both drugs act as agonists on bone and antagonists on breast. Raloxifene actually reduces breast cancer risk by 44-76% in high-risk women (MORE trial). (G&G, Ch. 48; K, Ch. 40)

SECTION 4: ADDITIONAL HIGH-YIELD MCQs

Q11. Which of the following about the GPER (GPR30) is TRUE?

A. It is a nuclear receptor like ERα B. It mediates rapid non-genomic effects of estrogen and is a G protein-coupled receptor C. Its knockout in mice causes complete reproductive failure D. GPER-selective agonists are already widely used therapeutically

Answer: B

Explanation: GPER (originally GPR30) is a G protein-coupled estrogen receptor that mediates rapid (non-genomic) effects of estrogen - including activation of MAPK/ERK, PI3K/Akt, and increases in intracellular cAMP and Ca2+. These effects occur within minutes, far faster than the hours needed for genomic transcription. Importantly, GPER knockout mice do NOT display reproductive dysfunction (so it is not essential for reproduction), but show altered physiological functions - suggesting a modulatory role. GPER-selective agonists are currently in early clinical trials for anti-tumor effects. (G&G, Ch. 48)

Q12. A 55-year-old postmenopausal woman presents with vasomotor symptoms (hot flushes, night sweats) and is found to have osteoporosis. She has no personal or family history of breast or endometrial cancer, no VTE history. The MOST appropriate hormonal therapy is:

A. Tamoxifen B. Raloxifene C. Low-dose combined HRT (estrogen + progestogen) D. Clomiphene

Answer: C

Explanation: Combined HRT (estrogen + progestogen) is the most effective treatment for vasomotor symptoms AND has proven bone-protective effects. Tamoxifen and raloxifene do not treat hot flushes (raloxifene actually worsens them). Clomiphene is used for ovulation induction, not menopause. In a woman with intact uterus, estrogen must always be combined with a progestogen to prevent unopposed estrogenic stimulation of the endometrium (risk of endometrial hyperplasia/cancer). The Women's Health Initiative studies showed HRT significantly increases risks of heart disease and breast cancer, so it is now reserved for short-term symptom relief. (G&G, Ch. 48; K, Ch. 40)

Q13. Conjugated equine estrogens (CEE) contain primarily:

A. Pure 17β-estradiol B. Estrone sulfate as the predominant component, plus equilin and other equine estrogens C. Estriol only D. Synthetic ethinyl estradiol

Answer: B

Explanation: CEE (e.g., Premarin) is extracted from the urine of pregnant mares. It contains a mixture of estrogen sulfates: estrone sulfate is the predominant component (~50%), plus equilin (a horse-specific estrogen, ~25%), 17α-dihydroequilin, 17α-estradiol, and other equine estrogens. After oral administration, these sulfated forms are hydrolyzed in the gut to yield active estrogens. CEE was the formulation used in the Women's Health Initiative study. (G&G, Ch. 48; KDT Ch. 22)

Q14. Which SERM acts as an estrogen ANTAGONIST on the hypothalamus-pituitary, thereby INCREASING FSH and LH?

A. Raloxifene B. Tamoxifen C. Clomiphene D. Fulvestrant

Answer: C

Explanation: Clomiphene is the classic example of a SERM used specifically because of its hypothalamic-pituitary antagonism. By blocking estrogen negative feedback at the pituitary and hypothalamus, it increases GnRH pulsatility and gonadotropin secretion (FSH and LH), driving follicular development and ovulation. Tamoxifen has similar hypothalamic effects but is rarely used for ovulation induction. Raloxifene at the hypothalamic-pituitary level may mildly increase LH but is not used clinically for this purpose. Fulvestrant has no clinical use for ovulation induction. (K, Ch. 40; G&G, Ch. 48)

Q15. Which of the following is a recognized benefit (not just contraceptive effect) of combined oral contraceptive pills?

A. Increased risk of ovarian cancer B. Reduced incidence of endometriosis and dysmenorrhea C. Increased risk of pelvic inflammatory disease D. Increased risk of ectopic pregnancy

Answer: B

Explanation: COCPs have many non-contraceptive benefits: reduced risk of ovarian cancer (40-80% reduction with long-term use), reduced endometrial cancer risk, reduced ovarian cysts, reduced benign breast disease, reduced ectopic pregnancy risk, reduced PID severity, reduced iron deficiency anemia (less blood loss), improvement in dysmenorrhea, endometriosis, acne, and hirsutism, and reduced risk of rheumatoid arthritis. The pill does NOT increase ovarian cancer or ectopic pregnancy risk - these are key negative distractors. (K, Ch. 40)

QUICK SUMMARY TABLE: SERMS AT A GLANCE

Drug	Breast	Uterus	Bone	Lipids	Clinical Use
Tamoxifen	Antagonist	Partial agonist	Agonist	↓LDL, no ↑HDL	Breast cancer Rx/prevention
Raloxifene	Antagonist	Neutral/antagonist	Agonist	↓LDL	Osteoporosis, breast cancer prevention
Clomiphene	Antagonist (hypo-pit)	-	-	-	Ovulation induction
Fulvestrant	Pure antagonist	Pure antagonist	-	-	ER+ metastatic breast cancer

MEMORY AIDS (KDT-style Mnemonics)

"SAFE" for estrogen actions:

Sexual characteristics (secondary) and endometrial proliferation
Anti-resorptive on bone (protects against osteoporosis)
Fat distribution (gynoid), and favorable lipids (↑HDL, ↓LDL)
Endocrine effects: negative feedback on LH/FSH (except mid-cycle positive surge)

SERMs - Remember "TREE":

Tamoxifen - uTeRus agonist (Endometrial cancer risk)
Raloxifene - uteRus Quiet (no endometrial risk, bone agonist, worsens hot flushes)
Enclomiphene/clomifene - pituitary antEstrogen → ovulation
Fulvestrant - Full antagonist, receptor degradation

References:

Goodman & Gilman's Pharmacological Basis of Therapeutics - Ch. 48: Estrogens and Progestins
Katzung's Basic and Clinical Pharmacology, 16e - Ch. 40: Reproductive Hormones
KD Tripathi: Essentials of Medical Pharmacology - Ch. 22: Sex Hormones

This is a shared conversation. Sign in to Orris to start your own chat.